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Influence of Interleukin-1α and Tumor Necrosis Factor-α 
Production on Corneal Graft Survival
Aim To determine pro-inflammatory cytokine secretion from hu-
man corneas with different pathology and to establish whether cyto-
kine profile influences corneal graft outcome.
Method Secretion of both proinflammatory cytokine interleukin 
(IL)-1α and tumor necrosis factor (TNF)-α was measured after culti-
vation of 47 corneas collected from corneal graft recipients suffering 
from different corneal diseases. Non-inflammatory corneal diseases 
were keratoconus (n = 8), keratoglobus (n = 2), bullous keratopathy 
(n = 11), and Groenouw stromal dystrophy type II (n = 2), whereas 
inflammatory included vascularized corneal scar (n = 14), rejected 
graft (n = 6), and corneal ulcer (n = 4). Corneas were cultivated at 
37°C for 24 hours and frozen until cytokine detection was measured 
by immunoassay. Donor corneas unsuitable for transplantation were 
used as controls (n = 7). Corneal graft recipients were followed at 
least 18 months and rejection rate was calculated for each group.
Results The median concentration of IL-1α secreted from corneas of 
recipients with non-inflammatory diseases was 2.47 pg/mm3 (range, 
0.13-9.95). In inflammatory corneal diseases, IL-1α concentration 
was significantly higher (median, 5.92 pg/mm3; range, 0.48-12.68; 
P = 0.005). IL-1α production in controls (median, 0.63 pg/mm3; 
range, 0.36-1.29 pg/mm3) was significantly lower than in inflam-
matory corneal diseases (P<0.001) and non-inflammatory diseases 
(P = 0.008). Low level of TNF-α was detected only in 5 cases of vas-
cularized corneal scars, 3 cases of bullous keratopathy, and 3 cases of 
graft rejection. Rejection rate was significantly higher in inflamma-
tory than in non-inflammatory group (46% vs <10%, respectively, 
P = 0.008). IL-1α and TNF-α were absent from all patient’s sera, 
confirming its local intra-ocular production.
Conclusion Increased production of IL-1α in corneal recipients 
with inflammatory diseases suggests its role in corneal graft rejection 
in humans.
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The intraocular microenvironment is an im-
mune-privileged site where immunogenic in-
flammation has been associated with immuno-
suppressive factors found in aqueous humor. The 
abrogation of the intraocular immune privilege is 
associated with the presence of proinflammato-
ry cytokines in uveitis (1,2) or allograft rejection 
(3,4). It seems that the character of immune re-
sponse at this specific site may be determined by 
the set of released cytokines (5-7).
The first hypothesis trying to explain the im-
mune privilege of the anterior eye chamber was 
that the antigens placed in the anterior chamber 
were sequestered, which was the reason for the af-
ferent blockage of the immune system (8). How-
ever, it has been found that antigens placed in the 
eye reach systemic circulation and prolonged sur-
vival of allografts in the anterior chamber has been 
explained by suppression of the delayed type hy-
persensitivity to the antigen introduced through 
the anterior chamber (9,10). The phenomenon 
where the inoculation of antigen via the anterior 
chamber depresses the cell-mediated immune re-
sponse to that specific antigen is called anterior 
chamber-associated immune deviation (11).
In animal models, transforming growth factor 
(TGF)-β2 was shown to play a critical role in the 
induction of anterior chamber-associated immune 
deviation (12,13). It was found in all free fluids 
that confer properties inducing anterior chamber-
associated immune deviation in vitro, ie, in aque-
ous humor, cerebrospinal liquid, and amniotic 
fluid (12,13). However, in animal models, the phe-
nomenon of anterior chamber-associated immune 
deviation is lost after corneal transplantation or 
when corneal inflammation is present (14).
Although the mechanisms of maintenance 
and loss of anterior chamber-associated immune 
deviation in the mouse eye are well explained, as 
in case of allograft transplantation, there are lim-
ited data on immune mechanisms following al-
lograft transplantation in the human eye. In our 
previous study, we found that high concentra-
tion of TGF-β2 and the absence of proinflamma-
tory tumor necrosis factor (TNF)-β was associat-
ed with high graft-acceptance rate in human eyes 
with non-inflammatory corneal diseases (15). 
This finding suggested that TGF-β2 might pro-
mote corneal graft survival also in human eyes, 
and even establish a form of anterior chamber-as-
sociated immune deviation in eyes with non-in-
flammatory corneal diseases.
Despite the immune privilege of the anterior 
chamber in the healthy eye, allograft rejection re-
mains the main cause of corneal graft failure be-
cause immune priviledge is lost in diseased cor-
neas (16). This is particularly true in eyes with 
present inflammation, where the rejection rate 
may exceed 50% (17). This occurs because im-
mune privilege can be abrogated in several ways, 
like in ocular inflammation, in the presence of 
Langerhans cells in central cornea, and after kera-
toplasty (14,18-20).
Experimental studies have implicated pro-
inflammatory cytokines as mediators of graft re-
jection in non-ocular tissue. In allografts such as 
heart, liver, or kidney, IL-1α and TNF-α mediate 
alloimmune response (21,22). Although the mo-
lecular mechanisms of ocular alloimmunity re-
main poorly understood, animal models provide 
evidence that proinflammatory cytokines, such 
as interleukin (IL)-1α and TNF-α, can modulate 
immune response to the corneal graft (3,4,23-
27). Moreover, local suppression of cytokine ac-
tivity by their antagonists, such as interleukin-
1 receptor antagonist (IL-1ra) and soluble TNF 
receptor, promotes corneal graft survival (28-32). 
Having in mind a significant benefit from such 
local treatment in the prevention of graft rejec-
tion in human eyes, we decided to determine 
whether IL-1α and TNF-α were produced by 
human corneal graft recipients similarly as they 
were in the animal model.
Subjects and methods
Subjects
Corneal tissue buttons were obtained from 
47 patients with various corneal diseases who 
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were surgically treated at our Department from 
2001 to 2003. Informed consent was obtained 
from all patients after the explanation of the na-
ture of the study. The study included 20 men and 
27 women, aged 20-70 years. Patients were divid-
ed into two groups according to the presence of 
inflammatory signs at the time of surgery. One 
group included patients with inflammatory cor-
neal diseases, as follows: vascularized corneal scar 
(n = 14), rejected graft (n = 6), and corneal ulcer 
(n = 4). The other group included patients with 
non-inflammatory corneal diseases, as follows: 
bullous keratopathy (n = 11), keratoconus with-
out hydrops (n = 8), keratoglobus (n = 2), and 
Groenouw stromal dystrophy type II (n = 2). 
Donor corneas unsuitable for transplantation 
were used as controls (n = 7). The inclusion cri-
teria for “inflammatory” group were the presence 
of one or more clinical signs of inflammation, 
such as neovascularization of the cornea, infiltra-
tion of the corneal stroma, and corneal ulcer. Al-
though different amount of inflammation can 
be observed at different time in each disease, our 
patients with the same diagnosis had a clinically 
similar degree of inflammation at the time of sur-
gery.
Human tissue used in these experiments was 
obtained and managed in accordance with the 
provisions of the Declaration of Helsinki (33).
Tissue and sera collection
Preoperatively, thickness of each affected 
and control cornea was measured by ultrasound 
pachymetry (Alcon Surgical 8700, Alcon, Forth 
Worth, TX, USA). Corneal and serum samples 
were collected from graft recipients during cor-
neal transplantation. Since we surgically treat 
our patients at approximately similar stage of dis-
ease, depending on the availability of the donor 
tissue, the duration of corneal disease in each pa-
tient was similar but not equal. Diameter of each 
excised corneal sample was recorded after treph-
ination. Corneal buttons were immediately cul-
tivated for 24 hours at 37°C in 0.5 mL of cor-
neal storage media (CorneaPrep, EuroBio, Les 
Ulis, France). After cultivation, corneas and their 
cultured supernatants were frozen and kept at -
21°C until cytokine detection.
Control corneas were obtained from healthy 
cadavers, with the informed consent of fami-
ly members according to the hospital protocol. 
Only corneas that were not suitable for trans-
plantation due to small number of endothelial 
cells were used.
Cytokine quantitation
Commercial kits for enzyme-linked immu-
nosorbent assay (ELISA; Quantikine, R&D Sys-
tems, Minneapolis, MN, USA) were used ac-
cording to the manufacturer’s instructions to 
determine concentrations of TNF-α and IL-1α 
in supernatants of cultivated corneas and in sera. 
ELISA assays were repeated twice for each cor-
nea. Cytokine concentration was calculated and 
adjusted for each cultivated cornea depending 
on its volume according to the following formu-
la: r2 × π × h (r – corneal diameter, π = 3.14, h – 
corneal thickness), and expressed per mm3 of tis-
sue. Due to the fact that corneal thickness might 
be influenced not only by higher number of cor-
neal cells but also by hydration of the cornea (due 
to dysfunctional endothelial cells), the results 
were also shown as cytokine concentration per 
mL of supernatant (without adjustment for cor-
neal thickness). Results were presented for over-
all cytokine production per group (inflammatory 
and non-inflammatory) and cytokine concentra-
tion per each corneal disease.
Association of cytokine concentration and 
clinical signs of graft reaction
Corneal graft recipients that donated their 
diseased corneas for this experiment were fol-
lowed up for at least 18 months after surgery and 
each clinical sign of graft reaction was recorded. 
Clinical signs of corneal graft reaction were the 
following: (a) epithelial rejection – appearance of 
the epithelial rejection line representing the zone 
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of destruction of donor epithelial cells; (b) sub-
epithelial infiltrates seen in the graft; (c) sudden 
onset of stromal edema and haze in a previously 
clear graft; and (d) presence of the endothelial re-
jection line or diffuse keratic precipitates on en-
dothelium. Diagnoses of allograft reaction were 
made only in technically successful grafts that 
had remained clear for at least 10-14 days after 
corneal transplantation, or 7 days in case of pre-
vious rejection. Cytokine concentrations found 
in corneas on the day of surgery were associated 
with the presence of graft rejection in the post-
operative period. Despite one or more episodes 
of graft reaction, some grafts would finally clear 
after administration of sub-conjunctival and sys-
temic steroid treatment. Those corneas were con-
sidered accepted. Corneal grafts that had clinical 
signs of graft reaction and had never cleared were 
considered rejected or failed.
Statistical analysis
Descriptive statistics was used to calculate 
median values with ranges and lower and up-
per quartiles. Kruskal-Wallis median test was 
used for between-group analysis of variance, with 
Man-Whitney test for post hoc analysis and be-
tween-group comparison. Kaplan-Meier curves 
were generated for the analysis of time period 
to corneal graft rejection. Differences were con-
sidered significant at P<0.05. The software used 
for data analysis was Statistica for Windows 5.0 
(StatSoft Inc., Tulsa, OK, USA).
Results
Interleukin-1α production
The median production of IL-1α of 5.92 pg/
mm3 (range, 0.48-12.68) in corneas with inflam-
matory diseases was significantly higher than that 
in corneas with non-inflammatory diseases (me-
dian, 2.47 pg/mm3; range, 0.13-9.95; P = 0.005) 
and control corneas (median, 0.63 pg/mm3; 
range 0.36-1.29; P<0.001) (Figure 1). There was 
also a significant difference in IL-1α production 
between the control corneas and corneas with 
non-inflammatory diseases (P = 0.008). IL-1α 
was absent from all patient’s sera, which con-
firmed its local intra-ocular production (Figure 
1).
There was higher secretion of IL-1α in cor-
neas with inflammatory corneal diseases, which 
are at increased clinical risk of graft rejection, 
than in control corneas or corneas with non-in-
flammatory diseases (Table 1). This was true for 
both the results expressed in pg/mm3, where ad-
justment for corneal thickness was made, and 
for the results expressed in pg/mL, where cor-
neal hydratation might influence the final result. 
The only exception was high IL-1α expression 
found in corneas with Groenouw dystrophy type 
II (median, 7.64 pg/mm3; range, 5.32-9.95), sim-
ilar to the values found in inflammatory diseases 
(Table 1).
TNF-α production
Low TNF-α levels were detected only in 5 
of 14 cases of vascularized corneal scars with 
the concentration ranging from 0.00 to 2.37 
pg/mm3 (median, 0.00 pg/mm3; in 3 of 11 cas-
Figure 1. Interleukin-(IL)1α production in diseased human cor-
neas and controls. Human corneas with inflammatory and non-
inflammatory diseases were harvested during corneal transplan-
tation, while control corneas were obtained from the eye bank, 
and cultivated for 24 hours. Concentration of IL-α in corneal 
supernatant was measured by ELISA, and expressed as median 
(closed square) with lower and upper quartiles (open square) and 
minimum and maximum (T lines). The median concentration of IL-
1α in inflammatory corneal diseases was significantly increased 
compared with non-inflammatory ones (P = 0.005) and controls 
(P<0.001, post hoc Man-Whitney test). Kruskal-Wallis ANOVA by 
ranks test confirmed the differences between the tested groups 
(P = 0.001).
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es with bullous keratopathy with concentration 
ranging from 0.00 to 1.50 pg/mm3 (median, 
0.00 pg/mm3), and in half of the patients with 
a rejected graft and concentration ranging from 
0.00 to 1.14 pg/mm3 (median, 0.09 pg/mm3). 
However, even this small production was a result 
of local TNF-α secretion because all sera samples 
were negative for TNF-α.
Association of cytokine concentration in 
collected corneas and clinical outcome of 
corneal grafts
Prospective 18-month follow-up of our pa-
tients showed that the rejection rate in group 
with inflammatory diseases was significantly 
higher than the rate in the group with non-in-
flammatory conditions (P = 0.005).
Graft rejection developed in 11 of 24 recipi-
ents with inflammatory corneal diseases who had 
increased IL-1α production at the time of surgery 
and in 2 of 23 recipients with non-inflammatory 
diseases who had low IL-1α concentration at the 
time of surgery (Table 2). This rejection rate was 
significantly higher in recipients with inflamma-
tory than in those with non-inflammatory cor-
neal diseases (Fisher exact test, P = 0.008).
Exceptions were the patients with corne-
al dystrophy that had no signs of graft reaction 
despite high IL-1α production. Kaplan-Meier 
curves showed that the time-to-graft rejection 
was significantly shorter and graft rejection was 
higher in the group of patients with inflamma-
tory diseases (Figure 2). Log-rank test showed 
significant difference between the groups in dis-
tribution of time-to-rejection of corneal graft 
(P = 0.004), and Fisher exact test showed signifi-
cant difference between the groups in frequency 
of rejection corneal graft (P = 0.008).
Discussion
This study showed that significantly more 
IL-1α was secreted from corneal buttons excised 
from corneal graft recipients with inflammato-
ry diseases than from those with non-inflamma-
tory diseases or controls. In the group of patients 
with inflammatory diseases, high concentra-
tion of IL-1α in recipient corneas at the time of 
surgery led to higher corneal graft rejection rate 
Table 1. Production of interleukin (IL)-1a in healthy corneas and corneas with inflammatory and non-inflammatory diseases*
Corneas


























































*Concentration of each cytokine was measured in corneal supernatant by enzyme-linked immunosorbent assay (ELISA).
†P = 0.005 vs non-inflammatory diseases and P<0.001 vs control corneas (Man-Whitney test).
‡P = 0.008 vs control corneas (Man-Whitney test).
§Results adjusted for corneal thickness.
¶Results expressed per mL supernatant.
Table 2. Production of pro-inflammatory cytokines interleu-
kin-1alpha (IL-1α) and tumor necrosis factor-alpha (TNF-α) in 
patients with rejected grafts*
Pro-inflammatory 
cytokines (pg/mm3)
Patient initials Diagnosis IL-1α TNF-α
Non-inflammatory diseases:
 D. P. keratoglobus  4.06 0.04
 M. M bullous keratopathy  6.30 0.11
Inflammatory diseases:
 G. D. rejected graft  4.20 0.16
 N. Č. rejected graft  7.51 0.53
 M. B. rejected graft  5.91 ND*
 F. O. corneal ulcer  6.68 ND
 P. B. corneal ulcer  8.34 ND
 F. P. corneal scar  7.18 1.90
 LJ. P. corneal scar  7.43 ND
 I. J. corneal scar  7.62 1.26
 N. N. corneal scar  5.93 ND
 I. P. corneal scar  2.78 ND
 M. P. corneal scar 12.68 ND
*ND – not detectable.
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than in patients with non-inflammatory diseas-
es. These findings suggest that locally produced 
IL-1α might be partly responsible on a molecu-
lar level for high rejection rate in the eyes with 
inflammatory corneal diseases. We were aware 
of the fact that the IL-1α concentration in the 
recipient’s graft bed might be different from the 
concentrations in the extracted central cornea 
due to different density of immune cells at the 
corneal periphery. However, it is reasonable to 
expect that recipients with high IL-1α concen-
tration in the extracted central cornea have even 
higher amount of IL-1α at the corneal periphery, 
because the graft bed contains higher amount of 
antigen-presenting and inflammatory cells then 
does the central corneal region (20,24), as graft 
bed is the only source of inflammatory cells from 
which they migrate into the central cornea.
Since corneal thickness could be increased 
not only due to the higher number of cells pro-
ducing the cytokine of interest, but also due to 
dysfunctional endothelial cells, which results 
in hydration of the cornea, the results were ex-
pressed in pg/mm3, where adjustment for corne-
al thickness was made, as well as in pg/mL, where 
corneal hydratation might influence final result. 
In both cases, level of IL-1α was significantly 
higher than that in control corneas. Thus, the de-
tected differences in IL-1α production between 
the groups were indeed the result of increased cy-
tokine production and not a false result due to 
higher hydration of a specific corneal sample.
Unexpectedly, patients with Groenouw dys-
trophy type II, which is a non-inflammatory cor-
neal disease, also had high concentrations of pro-
inflammatory cytokine IL-1α in their corneas at 
the time of surgery. No signs of graft rejection 
were recorded during the follow-up period, but 
there were only two patients with this disease in-
cluded in the study.
It is well known from clinical experience that 
patients suffering from inflammatory corneal 
diseases are at much higher risk of graft rejection; 
however, mediators of this phenomenon have yet 
to be determined (17). According to the avail-
able data from animal models, IL-1α promotes 
allograft rejection in the first graft by stimulation 
of the antigen-presenting cells and induction of 
corneal neovascularization (29). Further research 
in our laboratory is under way to determine if pa-
tients with increasing amount of corneal neovas-
cularization also have increased quantity of IL-1α 
in their corneas.
In the eyes that rejected a corneal graft, de-
spite having a low IL-1α concentration compara-
ble to the one measured in eyes with non-inflam-
matory corneal diseases, graft rejection rate was 
high. This indicates that in repeated human cor-
neal grafts, other cytokine(s) act as allograft rejec-
tion mediator(s).
IL-1α production in non-inflammatory cor-
neal diseases was significantly higher than in con-
trols. This finding implicates that the eyes clini-
cally considered before operation to be “without” 
any inflammation may in fact secrete proinflam-
matory cytokine from the corneas. However, 
graft rejection in these patients was low. This 
might be explained by the fact that a higher lev-
el of IL-1α production is needed to induce graft 
rejection, or that an antagonist of IL-1α activity 
is also secreted from the corneas of low-risk pa-
tients, thus preventing graft rejection develop-
Figure 2. Kaplan-Meier curves showed that time period to graft rejecti-
on was shorter and graft rejection was higher in inflammatory group of 
patients (P = 0.004). Circle – rejected corneas; plus sign – non-rejected 
corneas; full line – corneas with inflammatory diseases; dotted line – cor-
neas with non-inflammatory diseases.
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ment. In any case, preoperative clinical judgment 
of the “inflammation rate” does not seem to be as 
accurate as an objective measurement of cytokine 
concentration at the time of surgery.
Although TNF-α was also shown to be im-
portant graft rejection mediator in animal mod-
els (4,32), low TNF-α concentration found in 
this study, even in the eyes with inflammato-
ry corneal diseases, question its role in humans. 
Low TNF-α production in inflammatory cor-
neal diseases in humans might also be explained 
by a different timing of its secretion or indicate a 
need for more sensitive detection method such as 
mRNA expression by polymerase chain reaction.
We investigated production of IL-1α and 
TNF-α in diseased human corneas, because these 
two cytokines play a role in corneal graft rejec-
tion in animal model. The analysis of cytokine 
concentrations in the aqueous humor and cornea 
at the time of surgery can help not only in prog-
nosis of graft survival and, therefore, proper deci-
sion of postoperative treatment for each patient, 
but also in possible therapy with proinflamma-
tory cytokine antagonists or immunosuppres-
sive cytokine agonists. Previously, we investigated 
corneal graft prognosis in human recipients with 
high and low TGF-β2 concentrations in aqueous 
humor, and concluded that the loss of immune 
privilege, ie, low concentration of TGF-β2 in the 
anterior chamber, would increase graft rejection 
rate (15). According to that study, loss of immune 
privilege might also be explained by increased pro-
duction of IL-1α in the recipient cornea.
The present study showed that IL-1α and 
TNF-α were not the only parameters involved in 
the mediation of rejection reaction as the corre-
lation between grafting failure and the cytokine 
concentration was not that linear. Other param-
eters involved in the mediation of rejection have 
already been identified (34), whereas other still 
need to be investigated.
One of the limitations of this study was that 
we quantified IL-1α and TNF-α level by ELISA 
testing, which may not correspond to the bio-
logical activity of these proteins. Therefore, oth-
er testing procedures overcoming this limitation 
should be considered in future studies in the role 
of this cytokines in corneal grafting.
In conclusion, it has been shown in animal 
models that pro-inflammatory actions of IL-
1α may be abrogated by topical treatment with 
its antagonist, IL-1 receptor antagonist (Il-1ra). 
Topical treatment with IL-1ra can suppress cor-
neal neovascularization (35,36) and promote 
corneal allograft survival in animal eyes (28-31). 
Our results, although based on a relatively small 
sample, implicate that IL-1α is closely involved in 
corneal rejection in human subjects. Therefore, 
topical IL-1ra treatment may be useful also in hu-
man corneal graft recipients, by lowering the risk, 
or even preventing, corneal allograft rejection.
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